Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 132

Results For "EMA"

2403 News Found

Cadila Pharmaceuticals signs IIF with Odisha Government
News | December 08, 2022

Cadila Pharmaceuticals signs IIF with Odisha Government

The company will set-up a pharmaceuticals formulation manufacturing unit with an investment of Rs. 100 crore in Odisha


Wockhardt promoters sell stake
News | December 08, 2022

Wockhardt promoters sell stake

The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.


Govt. to create a vibrant ecosystem where women can flourish and harness full potential: Dr. Bharati
Policy | December 08, 2022

Govt. to create a vibrant ecosystem where women can flourish and harness full potential: Dr. Bharati

More women centric initiatives being the need of the hour for holistic development


Healthium divests its UK based continence care organization Clinisupplies
News | December 07, 2022

Healthium divests its UK based continence care organization Clinisupplies

Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio


Telemedicine service eSanjeevani achieves 8 crore teleconsultations
News | December 07, 2022

Telemedicine service eSanjeevani achieves 8 crore teleconsultations

The initiative has garnered the distinction of being the world’s largest government owned telemedicine platform


JB Pharma reduces price of Azmarda by 50%
News | December 06, 2022

JB Pharma reduces price of Azmarda by 50%

Move to increase affordability and accessibility for heart failure patients across the country


Auretics launched herbal cough syrup ‘Sedoril’
News | December 06, 2022

Auretics launched herbal cough syrup ‘Sedoril’

It offers quick relief in various types of Coughs, Colds and Sore Throat,


Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate
News | December 05, 2022

Valneva and Pfizer report antibody persistence data for lyme disease vaccine candidate

Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule


Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
News | December 05, 2022

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer


Jemperli RUBY phase III trial met its primary endpoint
Diagnostic Center | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival